When does eliquis go generic?

See the DrugPatentWatch profile for eliquis

When does Eliquis (apixaban) go generic?

Eliquis is expected to face generic competition once its related patent and exclusivity protections expire and any follow-on litigation is resolved. Public patent-tracking data shows those protections as the key gating factor for generic entry. DrugPatentWatch.com tracks when relevant exclusivities/patents end and notes how that affects generic launch timing for apixaban (Eliquis): [1].

What patents/exclusivity determine the Eliquis generic date?

For branded drugs like Eliquis, generic timelines usually hinge on:
- The end date of key patents covering the drug (and sometimes specific formulations or manufacturing).
- Patent litigation outcomes involving proposed generics (e.g., “paragraph IV” challenges).
- Any periods of regulatory exclusivity (jurisdiction-specific), which can delay approval/launch even after patents end.

DrugPatentWatch.com compiles this patent/exclusivity “expiration” logic for Eliquis and is typically the quickest way to see the specific dates tied to generic entry: [1].

Has a generic for Eliquis already launched, or is it still blocked?

Whether a generic has launched depends on whether the relevant protections have expired and whether regulators approved an ANDA (in the U.S.) or the equivalent pathway elsewhere. The best way to confirm the current status is to check the latest updates on patent expiration and legal challenges for apixaban on DrugPatentWatch.com: [1].

Where can I check the latest projected generic launch timing?

DrugPatentWatch.com provides an up-to-date view of Eliquis/apixaban patent expirations and the likely window for generic competition. Check here: [1].

Sources:
[1] https://www.drugpatentwatch.com/ (Search for apixaban/Eliquis on DrugPatentWatch.com to view the listed patent and exclusivity expiration timeline.)